ClinicalTrials.gg
RecruitingNCT06705816Updated Jun 18, 2026

Cognitive Function in Rett Syndrome During Trofinetide Treatment

An observational study in Rett Syndrome, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by University of Minnesota · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Rett Syndrome with a site in United States — 11 open to participants now, 21 under way, 5 of them phase 3. Rett Syndrome · United States.

Planned enrollment
19th of 21
20 · median 146
Started
2024
with 3 others
Observational
21 of 55
6 open now
Primary completion
2027-06
later than 8 of 20 live
Registered
48th of 55
by date

Among the 55 studies in Rett Syndrome with a site in United States, this one is the 19th largest by planned enrollment of the 21 observational ones that give a count, is one of 4 that started in 2024, is one of 21 observational ones, reaches primary completion later than 8 of the 20 other live ones, and was the 48th registered.

Rett Syndrome

96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.

Browse Rett Syndrome studies →

Open to participants now

11 of the 55 studies in Rett Syndrome with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Rett Syndrome with a site in United States, or all of them as a file.
02

Study summary

Assessing cognitive functions among individuals with severe intellectual and developmental disabilities (IDD), including RTT, is often challenging due to floor effects of many standardized assessment batteries in this population. In addition, deficits in motor function and verbal ability may obscure certain abilities in this population when using standard IQ measures. Remote eye-tracking tasks have been proposed as an alternative approach for assessing cognitive functions among individuals with severe IDD, because eye-tracking tasks can be designed to minimize the influence of gross motor and receptive language deficits on performance. Although several types of eye-tracking tasks have been evaluated in RTT, most have been implemented only at a single time-point. As a result, it is unclear whether these measures are stable over time, or sensitive to developmental changes or alterations to health status that occur in RTT (e.g., developmental regression, development of seizures, change in medication, etc.). With the recent FDA approval of trofinetide for the treatment of RTT, we have a novel opportunity to test the sensitivity of eye-tracking and other psychophysiological measures to treatment changes. Anecdotally, parents and clinicians have reported improvements in attention and alertness during trofinetide treatment, but currently available outcome measures do not capture these types of effects. Therefore, we propose to conduct a pilot trial of changes in measures of attention, oculomotor function, learning, and autonomic function, all collected using non-invasive measures, during trofinetide treatment. This is an observational within-subject design with a 4-week post-treatment assessment compared to two pre-treatment assessments. Additional optional follow-up assessments will be performed with families who are interested and returning for standard-of-care visits to Gillette or who are willing to travel for a research-only visit.

03

Conditions studied

  • Rett Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Any individuals who are initiating trofinetide treatment for RTT through the physicians associated with the Gillette Children's RTT clinic will be potentially eligible for participation, regardless of age.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any individuals who are initiating trofinetide treatment for RTT through the physicians associated with the Gillette Children's RTT clinic will be potentially eligible for participation, regardless of age. To enroll, participants must meet the following criteria:

    1. Provision of signed and dated form by the individual\'s parent/legal guardian
    2. Stated willingness to comply with all study procedures and availability for the duration of the study
    3. Documented diagnosis of Rett syndrome
    4. Participant is not showing active signs of developmental regression, defined as: no loss or degradation of ambulation within the past 6 months; no loss or degradation of hand function within the past 6 months; and no loss or degradation of verbal or non-verbal communication or social skills in the past 6 months.
    5. Participant's current pharmacological treatment regimen has been stable for at least 4 weeks.
    6. Seeking prescription for trofinetide through the Gillette Children's Rett syndrome clinic

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of a progressive medical or neurological condition that in the opinion of the investigator would interfere with the conduct of the study.
  2. Current systemic illness that is likely to result in the deterioration of the participant\'s condition during the study.
  3. Participants taking any other drug currently or within the past 30 days.
  4. Known, uncorrected visual impairment that would limit the ability to view images during eye-tracking tasks.
  5. Severe behavioral problems (i.e., aggression, property destruction, extreme hyperactivity) that would interfere with participation in study activities.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Study group

    Patients with Rett Syndrome who are interested in Trofinetide treatment

    Other: None interventional

Interventions

  • OtherNone interventional

    This is an observational study

06

What researchers measure

Primary outcomes

  1. Cognitive Function in Rett Syndrome During Trofinetide Treatment

    change in saccade latencies during the 'statistical learning' paradigm

    Time frame: baseline, 6weeks to 12 months

  2. Eye movement gaze fixations

    change in duration of gaze fixation to the correct image during the 'Looking While Listening' paradigm.

    Time frame: baseline, 6weeks to 12 months

Secondary outcomes

  1. Heart rate variability

    Change in baseline heart rate variability during sustained attention during eye-tracking tasks.

    Time frame: baseline, 6weeks to 12 months

  2. Heart rate suppression

    Change in baseline heart rate suppression during sustained attention during eye-tracking tasks.

    Time frame: baseline, 6weeks to 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Jun 2027, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2024
First posted
Nov 26, 2024
StartActual
Dec 1, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06705816
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Dec 1, 2024
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

Breanne Byiers
Contact
byier001@umn.edu
612-626-7892
Breanne Byiers
principal investigator · University of Minnesota

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion